BioNTech malaria vaccine study placed on clinical hold by USFDA

Malaria is a life-threatening disease spread to humans by some types of mosquitoes. It is mostly found in tropical countries. It is preventable and curable.

The infection is caused by a parasite and does not spread from person to person.

Symptoms can be mild or life-threatening. Mild symptoms are fever, chills and headache. Severe symptoms include fatigue, confusion, seizures, and difficulty breathing.

Read also: New BNT162b2 XBB Vaccine Provides Significant Additional Protection Against COVID-19 Hospitalization and ED Visits: Study

Infants, children under 5 years, pregnant women and girls, travellers and people with HIV or AIDS are at higher risk of severe infection.

Malaria can be prevented by avoiding mosquito bites and with medicines. 

Medical Dialogues team had earlier reported that BioNTech SE and Biotheus have announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company.